KRYS
Neutral signalScored 2026-08-15 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Krystal Biotech, Inc.
- Nom
- Krystal Biotech, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $9.2B
- Employés
- 295
- PDG
- Krish S. Krishnan
- Site web
- https://www.krystalbio.com
- Marché
- ABEOMGTXRCKTRGNXSANA
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 75 000 titres (~25 866 962,50 $ US)
- Insiders
- Krishnan SumaKrishnan Krish SROSSI DINO A
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$308,041
Avg sell (VWAP, 90d window) $364.98 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$294,711 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-04
- Last synced
-
2026-09-10 10:26:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Krishnan Krish S | Sell · S · 10b5-1 | 405 | $366.56 | $148,455 | Form 4 |
| 2026-09-04 | Krishnan Suma | Sell · S · 10b5-1 | 399 | $366.56 | $146,256 | Form 4 |
| 2026-08-14 | ROSSI DINO A | Sell · S | 40 | $333.23 | $13,329 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-12-11 | Chris Jacobs | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-15 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
KRYS exhibits genuinely strong financial fundamentals — clean balance sheet, high margins, and a clear profitability trajectory — which anchor the score above distressed levels.
The first sentence of the analysis written for KRYS on 2026-08-15 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 9.95 · operating margin 41%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 92.6% | 93.1% | 93.9% | 0.0% | 0.0% | |
| Ebit Margin | 48.7% | 35.5% | -191.8% | 0.0% | 0.0% | |
| Ebitda Margin | 50.4% | 37.8% | -180.1% | 0.0% | 0.0% | |
| Operating Profit Margin | 41.5% | 22.6% | -216.4% | 0.0% | 0.0% | |
| Pretax Profit Margin | 48.7% | 32.8% | 25.4% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 52.6% | 30.7% | 21.6% | 0.0% | 0.0% | |
| Net Profit Margin | 52.6% | 30.7% | 21.6% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 52.6% | 30.7% | 21.6% | 0.0% | 0.0% | |
| Current Ratio | 9.953 | 7.275 | 17.765 | 13.304 | 17.185 | |
| Quick Ratio | 9.560 | 7.015 | 17.554 | 13.304 | 17.185 | |
| Solvency Ratio | 1.850 | 0.876 | 0.424 | -3.771 | -2.070 | |
| Cash Ratio | 4.821 | 3.381 | 10.828 | 5.612 | 13.259 | |
| Price To Earnings Ratio | 34.822 | 50.212 | 310.150 | -14.430 | -22.348 | |
| Price To Earnings Growth Ratio | 0.274 | 0.074 | -2.891 | -0.191 | -0.269 | |
| Forward Price To Earnings Growth Ratio | 0.274 | 0.074 | -2.891 | -0.191 | -0.269 | |
| Price To Earnings Diluted Ratio | 36.044 | 52.220 | 318.103 | -14.430 | -22.348 | |
| Price To Earnings Diluted Growth Ratio | 0.282 | 0.078 | -2.970 | -0.191 | -0.269 | |
| Price To Book Ratio | 5.851 | 4.733 | 4.326 | 3.867 | 2.616 | |
| Price To Sales Ratio | 18.338 | 15.418 | 66.446 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | 37.773 | 37.583 | -33.485 | -13.152 | -13.354 | |
| Price To Operating Cash Flow Ratio | 35.526 | 36.293 | -37.934 | -20.081 | -32.389 | |
| Debt To Assets Ratio | 0.007 | 0.007 | 0.010 | 0.016 | 0.013 | |
| Debt To Equity Ratio | 0.008 | 0.008 | 0.010 | 0.017 | 0.014 | |
| Debt To Capital Ratio | 0.008 | 0.008 | 0.010 | 0.017 | 0.013 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.094 | 1.116 | 1.051 | 1.069 | 1.055 | |
| Working Capital Turnover Ratio | 0.498 | 0.486 | 0.111 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | 1.951 | 1.210 | -2.683 | -3.486 | -1.863 | |
| Operating Cash Flow Sales Ratio | 0.516 | 0.425 | -1.752 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.941 | 0.966 | 1.133 | 1.527 | 2.426 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -44.389 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -45.761 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 21.508 | 16.998 | -10.972 | -11.258 | -5.974 | |
| Capital Expenditure Coverage Ratio | 16.807 | 29.122 | -7.526 | -1.898 | -0.702 | |
| Dividend Paid And Capex Coverage Ratio | 16.807 | 29.122 | -7.526 | -1.898 | -0.702 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.919 | 37.682 | -33.055 | -15.979 | -18.413 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 92.6% | ▼-0.5% | ▲36.7% |
| Ebit Margin | 48.7% | ▲13.2% | ▲70.2% |
| Ebitda Margin | 50.4% | ▲12.5% | ▲68.8% |
| Operating Profit Margin | 41.4% | ▲18.8% | ▲71.9% |
| Pretax Profit Margin | 48.7% | ▲15.9% | ▲27.3% |
| Continuous Operations Profit Margin | 52.6% | ▲21.9% | ▲31.7% |
| Net Profit Margin | 52.6% | ▲21.9% | ▲31.7% |
| Bottom Line Profit Margin | 52.6% | ▲21.9% | ▲31.7% |
| Current Ratio | 9.953 | ▲2.678 | ▼-3.143 |
| Quick Ratio | 9.560 | ▲2.545 | ▼-3.364 |
| Solvency Ratio | 1.850 | ▲0.975 | ▲2.389 |
| Cash Ratio | 4.821 | ▲1.440 | ▼-2.759 |
| Price To Earnings Ratio | 34.822 | ▼-15.389 | ▼-36.859 |
| Price To Earnings Growth Ratio | 0.274 | ▲0.201 | ▲0.875 |
| Forward Price To Earnings Growth Ratio | 0.274 | ▲0.201 | ▲0.875 |
| Price To Earnings Diluted Ratio | 36.044 | ▼-16.176 | ▼-37.874 |
| Price To Earnings Diluted Growth Ratio | 0.282 | ▲0.204 | ▲0.896 |
| Price To Book Ratio | 5.851 | ▲1.118 | ▲1.573 |
| Price To Sales Ratio | 18.338 | ▲2.920 | ▼-1.702 |
| Price To Free Cash Flow Ratio | 37.773 | ▲0.190 | ▲34.700 |
| Price To Operating Cash Flow Ratio | 35.526 | ▼-0.767 | ▲39.243 |
| Debt To Assets Ratio | 0.007 | ▲0.000 | ▼-0.004 |
| Debt To Equity Ratio | 0.008 | -0.000 | ▼-0.004 |
| Debt To Capital Ratio | 0.008 | -0.000 | ▼-0.004 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.094 | ▼-0.022 | ▲0.017 |
| Working Capital Turnover Ratio | 0.498 | ▲0.012 | ▲0.279 |
| Operating Cash Flow Ratio | 1.951 | ▲0.741 | ▲2.925 |
| Operating Cash Flow Sales Ratio | 0.516 | ▲0.091 | ▲0.678 |
| Free Cash Flow Operating Cash Flow Ratio | 0.941 | ▼-0.025 | ▼-0.458 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲8.878 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲9.152 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 21.508 | ▲4.511 | ▲19.448 |
| Capital Expenditure Coverage Ratio | 16.807 | ▼-12.315 | ▲9.647 |
| Dividend Paid And Capex Coverage Ratio | 16.807 | ▼-12.315 | ▲9.647 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.919 | ▼-3.763 | ▲33.088 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $7.14B | $4.48B | $3.37B | $2.02B | $1.55B | |
| Enterprise value | $6.65B | $4.14B | $3.02B | $1.87B | $1.22B | |
| EV / Sales | 17.09x | 14.26x | 59.54x | 0.00x | 0.00x | |
| EV / Op. cash flow | 33.10x | 33.56x | -33.99x | -18.56x | -25.44x | |
| EV / Free cash flow | 35.20x | 34.75x | -30.00x | -12.16x | -10.49x | |
| EV / EBITDA | 33.92x | 37.68x | -33.05x | -15.98x | -18.41x | |
| Net debt / EBITDA | -2.48x | -3.07x | 3.83x | 1.31x | 5.03x | |
| Current ratio | 9.95x | 7.28x | 17.77x | 13.30x | 17.18x | |
| Income quality | 0.98x | 1.38x | -8.12x | 0.72x | 0.69x | |
| Graham number | $82 | $48 | $16 | — | — | |
| Graham net-net | $29 | $20 | $19 | $13 | $18 | |
| Tax burden | 108.1% | 93.5% | 84.8% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 92.4% | -13.3% | 116.5% | 102.2% | |
| Working capital | $921.7M | $640.0M | $554.8M | $354.9M | $416.5M | |
| Invested capital | $1.08B | $801.5M | $723.0M | $524.7M | $536.1M | |
| Return on assets | 15.4% | 8.4% | 1.3% | -25.1% | -11.1% | |
| Operating ROA | 13.5% | 7.0% | -15.9% | -24.5% | -14.6% | |
| Return on tangible assets | 15.4% | 8.4% | 1.3% | -25.1% | -11.1% | |
| Return on equity | 16.8% | 9.4% | 1.4% | -26.8% | -11.7% | |
| Return on invested capital | 13.1% | 6.4% | -11.8% | -27.3% | -11.3% | |
| Return on capital employed | 13.1% | 6.9% | -14.0% | -27.4% | -11.4% | |
| Earnings yield | 2.9% | 2.0% | 0.3% | -6.9% | -4.5% | |
| Free cash flow yield | 2.6% | 2.7% | -3.0% | -7.6% | -7.5% | |
| Capex / Op. cash flow | 5.9% | 3.4% | -13.3% | -52.7% | -142.6% | |
| Capex / Depreciation | 182.4% | 63.1% | 235.7% | 1306.5% | 2467.9% | |
| Capex / Sales | 3.1% | 1.5% | 23.3% | 0.0% | 0.0% | |
| SG&A / Sales | 37.7% | 39.1% | 194.1% | 0.0% | 0.0% | |
| R&D / Sales | 14.9% | 18.4% | 91.6% | 0.0% | 0.0% | |
| Stock comp / Sales | 14.0% | 16.9% | 78.8% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 120d | 132d | 303d | 0d | 0d | |
| Days payables outstanding | 41d | 91d | 218d | 0d | 0d | |
| Operating cycle | 633d | 614d | 1127d | 0d | 0d | |
| Cash conversion cycle | 592d | 523d | 909d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-03 Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? KRYS'' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
- 2026-09-03 Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.
- 2026-09-02 Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? Krystal Biotech (KRYS) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-14 Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.
- 2026-08-04 Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.
- 2026-08-03 Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
- 2026-08-03 Krystal Biotech Q2 Earnings Call Highlights Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.
- 2026-08-03 Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.
- 2026-08-03 Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results $119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,” said Krish S.
- 2026-07-29 Krystal Biotech: International Expansion And A Vibrant Pipeline Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. KRYS''s international Vyjuvek launches in Europe and Japan are accelerating topline growth, with further expansion into Italy, Spain, and the UK expected to boost revenues. KRYS''s pipeline, leveraging its proprietary HSV-1 platform, spans respiratory, ophthalmology, oncology, and aesthetics, reducing future reliance on Vyjuvek.